CRISPR Therapeutics AG
CRSP
$56.25
-$0.43-0.76%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 48.96% | -53.35% | -264.49% | 56.59% | 32.01% |
| Total Depreciation and Amortization | -4.65% | -1.84% | -2.19% | 2.17% | -2.19% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -93.93% | 374.21% | 230.76% | -53.63% | -5.45% |
| Change in Net Operating Assets | 166.07% | -130.11% | 325.21% | 39.65% | -484.71% |
| Cash from Operations | 25.68% | -111.10% | -7.83% | 53.20% | -11.85% |
| Capital Expenditure | 36.75% | 43.20% | 18.90% | -15.98% | 69.02% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -269.99% | 458.56% | -118.43% | 165.73% | -27.88% |
| Cash from Investing | -270.38% | 454.22% | -118.67% | 165.49% | -27.34% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 13,042.87% | -78.67% | -37.26% | 75.06% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 13,042.87% | -78.67% | -37.26% | 75.06% | 2,168.67% |
| Foreign Exchange rate Adjustments | -133.75% | 95.12% | 147.13% | -216.00% | 3,650.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 323.45% | 34.10% | -186.89% | 128.05% | -16.08% |